I am thinking that the CC delay is too allow time
Post# of 148281
It is likely that both the FDA and MHRA are waiting for the CD12 interim results before granting an EUA. The CD12 trial could have safety and/or efficacy issues as so many phase 3 trials have had. It would be very bad for the agencies to grant approval and then the CD12 phase 3 trial fails. My 2 cents.